Carret Asset Management LLC Reduces Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Carret Asset Management LLC lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.4% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 7,807 shares of the medical research company’s stock after selling 35 shares during the period. Carret Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $4,538,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in TMO. Northwest Financial Advisors purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $29,000. True Wealth Design LLC increased its holdings in Thermo Fisher Scientific by 1,275.0% in the 4th quarter. True Wealth Design LLC now owns 55 shares of the medical research company’s stock worth $29,000 after acquiring an additional 51 shares in the last quarter. Pineridge Advisors LLC bought a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $39,000. Cape Investment Advisory Inc. boosted its position in shares of Thermo Fisher Scientific by 52.0% in the fourth quarter. Cape Investment Advisory Inc. now owns 76 shares of the medical research company’s stock worth $40,000 after purchasing an additional 26 shares during the period. Finally, Raleigh Capital Management Inc. raised its position in shares of Thermo Fisher Scientific by 49.1% during the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 27 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total value of $5,672,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $70,238,340.48. The transaction was disclosed in a filing with the SEC, which is available at this link. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the sale, the senior vice president now directly owns 13,083 shares in the company, valued at approximately $7,430,359.02. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $70,238,340.48. The disclosure for this sale can be found here. Insiders sold 22,000 shares of company stock worth $12,532,780 in the last three months. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.3 %

TMO traded up $1.68 during trading on Wednesday, reaching $535.61. The company had a trading volume of 907,102 shares, compared to its average volume of 1,544,136. The company has a quick ratio of 1.33, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82. The stock has a market cap of $204.45 billion, a P/E ratio of 34.52, a PEG ratio of 2.58 and a beta of 0.77. The business has a 50 day simple moving average of $573.89 and a 200-day simple moving average of $563.61.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The company had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Friday, June 14th will be issued a dividend of $0.39 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on TMO shares. Jefferies Financial Group reaffirmed a “buy” rating and issued a $650.00 target price (up previously from $600.00) on shares of Thermo Fisher Scientific in a report on Monday, June 3rd. The Goldman Sachs Group lifted their target price on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Robert W. Baird dropped their price target on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday, April 25th. Evercore ISI dropped their target price on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating for the company in a research report on Tuesday. Finally, HSBC boosted their price target on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a research note on Tuesday, April 30th. Five equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $606.47.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.